Energy metabolism and drug efflux in mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2491-2503

  Black, Philippa A ^a   Warren, Robin M ^a   Louw, Gail E ^a   Van Helden, Paul D ^a   Victor, Thomas C ^a   Kana, Bavesh D ^b,c  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ADENOSINE TRIPHOSPHATE; BEDAQUILINE; MENAQUINONE; MULTIDRUG RESISTANCE PROTEIN; NIGERICIN; PHENOTHIAZINE DERIVATIVE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; VALINOMYCIN; BACTERIAL PROTEIN;

ACTIVE TRANSPORT; CLINICAL TRIAL (TOPIC); DRUG DIFFUSION; DRUG EFFLUX; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERANCE; DRUG TRANSPORT; EFFUSION; ELECTRON; ENERGY METABOLISM; ENERGY YIELD; GENE MUTATION; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTON MOTIVE FORCE; RESPIRATORY CHAIN; REVIEW; METABOLISM; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

ADENOSINE TRIPHOSPHATE; BACTERIAL PROTEINS; BIOLOGICAL TRANSPORT; ENERGY METABOLISM; MYCOBACTERIUM TUBERCULOSIS; PROTON-MOTIVE FORCE;

EID: 84898622291     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02293-13     Document Type: Review

References (161)

1. WHO. 2013. Global tuberculosis report 2013. http://www.who.int/tb/ publications/global-report/en/.
2. Zumla A, Raviglione M, Hafner R, von Reyn CF. 2013. Tuberculosis. N. Engl. J. Med. 368:745-755. http://dx.doi.org/10.1056/NEJMra1200894.
3. Marais BJ, Zumla A. 2013. History of tuberculosis and drug resistance. N. Engl. J. Med. 368:88-89. http://dx.doi.org/10.1056/NEJMc1212308.
4. Zumla A, Nahid P, Cole ST. 2013. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12: 388-404. http://dx.doi.org/10.1038/nrd4001.
5. Sarathy JT, Dartois V, Lee EJD. 2012. The role of transport mechanisms in Mycobacterium tuberculosis drug resistance in tolerance. Pharmaceuticals (Basel) 5:1210-1235. http://dx.doi.org/10.3390/ph5111210.
6. Cook GM, Berney M, Gebhard S, Heinemann M, Cox RA, Danilchanka O, Niederweis M. 2009. Physiology of mycobacteria. Adv. Microb. Physiol. 55:81-182, 318-319. http://dx.doi.org/10.1016/S0065-2911(09)05502-7.
7. Kana BD, Machowski E, Schechter N, Shin JT, Rubin H, Mizrahi V. 2009. Electron transport and respiration, p 35-64. In Parish T, Brown A (ed), Mycobacterium: genomics and molecular biology. Horizon Press, London, United Kingdom.
8. Bald D, Koul A. 2010. Respiratory ATP synthesis: the new generation of mycobacterial drug targets? FEMS Microbiol. Lett. 308:1-7. http://dx.doi.org/10. 1111/j.1574-6968.2010.01959.x.
9. Boshoff HIM, Barry CE. 2005. Tuberculosis-metabolism and respiration in the absence of growth. Nat. Rev. Microbiol. 3:70-80. http://dx.doi.org/10.1038/ nrmicro1065.
10. Neijssel OM, Teixeira de Mattos MJ. 1994. The energetics of bacterial growth: a reassessment. Mol. Microbiol. 13:172-182.
11. Fillingame RH. 1997. Coupling Htransport and ATP synthesis in F1F0-ATP synthases: glimpses of interacting parts in a dynamic molecular machine. J. Exp. Biol. 200:217-224.
12. Unden G, Bongaerts J. 1997. Alternative respiratory pathways of Escherichia coli: energetics and transcriptional regulation in response to electron acceptors. Biochim. Biophys. Acta 1320:217-234. http://dx.doi.org/10. 1016/S0005-2728(97)00034-0.
13. Lancaster CR, Kröger A. 2000. Succinate: quinone oxidoreductases: new insights from X-ray crystal structures. Biochim. Biophys. Acta 1459:422-431. http://dx.doi.org/10.1016/S0005-2728(00)00180-8.
14. Dhiman RK, Mahapatra S, Slayden RA, Boyne ME, Lenaerts A, Hinshaw JC, Angala SK, Chatterjee D, Biswas K, Narayanasamy P, Kurosu M, Crick DC. 2009. Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. Mol. Microbiol. 72:85-97. http://dx.doi.org/10.1111/j.1365-2958.2009.06625.x.
15. Kana BD, Weinstein EA, Avarbock D, Dawes SS, Rubin H, Mizrahi V. 2001. Characterization of the cydAB-encoded cytochrome bd oxidase from Mycobacterium smegmatis. J. Bacteriol. 183:7076-7086. http://dx.doi.org/10.1128/JB.183.24. 7076-7086.2001.
16. Matsoso LG, Kana BD, Crellin PK, Lea-Smith DJ, Pelosi A, Powell D, Dawes SS, Rubin H, Coppel RL, Mizrahi V. 2005. Function of the cytochrome bc1-Aa3 branch of the respiratory network in mycobacteria and network adaptation occurring in response to its disruption. J. Bacteriol. 187:6300-6308. http://dx.doi.org/10.1128/JB.187.18.6300-6308.2005.
17. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544. http://dx.doi.org/10.1038/31159.
18. Weinstein EA, Yano T, Li L-S, Avarbock D, Avarbock A, Helm D, McColm AA, Duncan K, Lonsdale JT, Rubin H. 2005. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc. Natl. Acad. Sci. U. S. A. 102:4548-4553. http://dx.doi.org/10.1073/pnas.0500469102.
19. Shi L, Sohaskey CD, Kana BD, Dawes S, North RJ, Mizrahi V, Gennaro ML. 2005. Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc. Natl. Acad. Sci. U. S. A. 102:15629-15634. http://dx.doi.org/10.1073/pnas.0507850102.
20. Rao SPS, Alonso S, Rand L, Dick T, Pethe K. 2008. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 105:11945-11950. http://dx.doi.org/10.1073/pnas.0711697105.
21. Velmurugan K, Chen B, Miller JL, Azogue S, Gurses S, Hsu T, Glickman M, Jacobs WR, Jr, Porcelli SA, Briken V. 2007. Mycobacterium tuberculosis nuoG is a virulence gene that inhibits apoptosis of infected host cells. PLoS Pathog. 3:e110. http://dx.doi.org/10.1371/journal.ppat.0030110.
22. Miller JL, Velmurugan K, Cowan MJ, Briken V. 2010. The type I NADH dehydrogenase of Mycobacterium tuberculosis counters phagosomal NOX2 activity to inhibit TNF-Alpha-mediated host cell apoptosis. PLoS Pathog. 6:e1000864. http://dx.doi.org/10.1371/journal.ppat.1000864.
23. Blomgran R, Desvignes L, Briken V, Ernst JD. 2012. Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells. Cell Host Microbe 11:81-90. http://dx.doi.org/10.1016/j.chom. 2011.11.012.
24. Sassetti CM, Boyd DH, Rubin EJ. 2003. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48: 77-84. http://dx.doi.org/10.1046/j.1365-2958.2003.03425.x.
25. McAdam RA, Quan S, Smith DA, Bardarov S, Betts JC, Cook FC, Hooker EU, Lewis AP, Woollard P, Everett MJ, Lukey PT, Bancroft GJ, Jacobs WR, Jr, Duncan K. 2002. Characterization of a Mycobacterium tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulence. Microbiology 148:2975-2986.
26. Kurokawa T, Sakamoto J. 2005. Purification and characterization of succinate:menaquinone oxidoreductase from Corynebacterium glutamicum. Arch. Microbiol. 183:317-324. http://dx.doi.org/10.1007/s00203-005-0775-8.
27. Eoh H, Rhee KY. 2013. Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 110:6554-6559. http://dx.doi.org/10.1073/pnas.1219375110.
28. Truglio JJ, Theis K, Feng Y, Gajda R, Machutta C, Tonge PJ, Kisker C. 2003. Crystal structure of Mycobacterium tuberculosis MenB, a key enzyme in vitamin K2 biosynthesis. J. Biol. Chem. 278:42352-42360. http://dx.doi.org/10. 1074/jbc.M307399200.
29. Collins MD, Goodfellow M, Minnikin DE, Alderson G. 1985.Menaquinone composition of mycolic acid-containing actinomycetes and some sporoactinomycetes. J. Appl. Microbiol. 58:77-86.
30. Collins MD, Jones D. 1981. Distribution of isoprenoid quinone structural types in bacteria and their taxonomic implication. Microbiol. Rev. 45:316-354.
31. Pandya KP, King HK. 1966. Ubiquinone and menaquinone in bacteria: a comparative study of some bacterial respiratory systems. Arch. Biochem. Biophys. 114:154-157. http://dx.doi.org/10.1016/0003-9861(66)90316-X.
32. Debnath J, Siricilla S, Wan B, Crick DC, Lenaerts AJ, Franzblau SG, Kurosu M. 2012. Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis. J. Med. Chem. 55:3739-3755. http://dx.doi.org/10.1021/jm201608g.
33. Sohaskey CD. 2005. Regulation of nitrate reductase activity in Mycobacterium tuberculosis by oxygen and nitric oxide. Microbiology 151:3803-3810. http://dx.doi.org/10.1099/mic.0.28263-0.
34. Malm S, Tiffert Y, Micklinghoff J, Schultze S, Joost I, Weber I, Horst S, Ackermann B, Schmidt M, Wohlleben W, Ehlers S, Geffers R, Reuther J, Bange FC. 2009. The roles of the nitrate reductase NarGHJI, the nitrite reductase NirBD and the response regulator GlnR in nitrate assimilation of Mycobacterium tuberculosis. Microbiology 155:1332-1339. http://dx.doi.org/10.1099/mic.0. 023275-0.
35. Sohaskey CD. 2008. Nitrate enhances the survival of Mycobacterium tuberculosis during inhibition of respiration. J. Bacteriol. 190:2981-2986. http://dx.doi.org/10.1128/JB.01857-07.
36. Sohaskey CD, Wayne LG. 2003. Role of narK2X and narGHJI in hypoxic upregulation of nitrate reduction by Mycobacterium tuberculosis. J. Bacteriol. 185:7247-7256. http://dx.doi.org/10.1128/JB.185.24.7247-7256.2003.
37. Homolka S, Niemann S, Russell DG, Rohde KH. 2010. Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival. PLoS Pathog. 6:e1000988. http://dx.doi.org/10.1371/ journal.ppat.1000988.
38. Fenhalls G, Stevens L, Moses L, Bezuidenhout J, Betts JC, van Helden P, Lukey PT, Duncan K. 2002. In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions. Infect. Immun. 70:6330-6338. http://dx.doi.org/10.1128/IAI.70. 11.6330-6338.2002.
39. Kruh NA, Troudt J, Izzo A, Prenni J, Dobos KM. 2010. Portrait of a pathogen: the Mycobacterium tuberculosis proteome in vivo. PLoS One 5:e13938. http://dx.doi.org/10.1371/journal.pone.0013938.
40. Aly S, Wagner K, Keller C, Malm S, Malzan A, Brandau S, Bange FC, Ehlers S. 2006. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J. Pathol. 210:298-305. http://dx.doi.org/10.1002/path.2055.
41. Tan MP, Sequeira P, Lin WW, Phong WY, Cliff P, Ng SH, Lee BH, Camacho L, Schnappinger D, Ehrt S, Dick T, Pethe K, Alonso S. 2010.Nitrate respiration protects hypoxic Mycobacterium tuberculosis against acid-And reactive nitrogen species stresses. PLoS One 5:e13356. http://dx.doi.org/10.1371/journal.pone. 0013356.
42. Akhtar S, Khan A, Sohaskey CD, Jagannath C, Sarkar D. 2013. Nitrite reductase NirBD is induced and plays an important role during in vitro dormancy of Mycobacterium tuberculosis. J. Bacteriol. 195:4592-4599. http://dx.doi.org/ 10.1128/JB.00698-13.
43. Watanabe S, Zimmermann M, Goodwin MB, Sauer U, Barry CE, Boshoff HI. 2011. Fumarate reductase activity maintains an energized membrane in anaerobic Mycobacterium tuberculosis. PLoS Pathog. 7:e1002287. http://dx.doi.org/10.1371/ journal.ppat.1002287.
44. Butlin JD, Cox GB, Gibson F. 1971. Oxidative phosphorylation in Escherichia coli K12. Mutations affecting magnesium ion-or calcium ion-stimulated adenosine triphosphatase. Biochem. J. 124:75-81.
45. Feniouk BA, Suzuki T, Yoshida M. 2007. Regulatory interplay between proton motive force, ADP, phosphate, and subunit epsilon in bacterial ATP synthase. J. Biol. Chem. 282:764-772. http://dx.doi.org/10.1074/jbc.M606321200.
46. Santana M, Ionescu MS, Vertes A, Longin R, Kunst F, Danchin A, Glaser P. 1994. Bacillus subtilis F0F1 ATPase: DNA sequence of the atp operon and characterization of atp mutants. J. Bacteriol. 176:6802-6811.
47. Priya R, Biukovic G, Manimekalai MS, Lim J, Rao SP, Gruber G. 2013. Solution structure of subunit (201-204) of the Mycobacterium tuberculosis F-ATP synthase and the unique loop of-165-178, representing a novel TB drug target. J. Bioenerg. Biomembr. 45:121-129. http://dx.doi.org/10.1007/s10863-012-9486-4.
48. Biukovic G, Basak S, Manimekalai MS, Rishikesan S, Roessle M, Dick T, Rao SP, Hunke C, Grüber G. 2013. Variations of subunit epsilon of the Mycobacterium tuberculosis F1F0 ATP synthase and a novel model for mechanism of action of the TB drug TMC207. Antimicrob. Agents Chemother. 57:168-176. http://dx.doi.org/10.1128/AAC.01039-12.
49. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J, Bald D, Andries K. 2007. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3:323-324. http://dx.doi.org/10.1038/nchembio884.
50. Sala C, Haouz A, Saul FA, Miras I, Rosenkrands I, Alzari PM, Cole ST. 2009. Genome-wide regulon and crystal structure of BlaI (Rv1846c) from Mycobacterium tuberculosis. Mol. Microbiol. 71:1102-1116. http://dx.doi.org/10. 1111/j.1365-2958.2008.06583.x.
51. Boshoff HIM, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE. 2004. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 279:40174-40184. http://dx.doi.org/10.1074/jbc.M406796200.
52. Wilke MS, Hills TL, Zhang H-Z, Chambers HF, Strynadka NCJ. 2004. Crystal structures of the Apo and penicillin-Acylated forms of the BlaR1 beta-lactam sensor of Staphylococcus aureus. J. Biol. Chem. 279:47278-47287. http://dx.doi.org/10.1074/jbc.M407054200.
53. Lun DS, Sherrid A, Weiner B, Sherman DR, Galagan JE. 2009. A blind deconvolution approach to high-resolution mapping of transcription factor binding sites from ChIP-seq data. Genome Biol. 10:R142. http://dx.doi.org/10. 1186/gb-2009-10-12-r142.
54. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RPG, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360:2397-2405. http://dx.doi.org/10.1056/NEJMoa0808427.
55. Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, Göhlmann HWH, Willebrords R, Poncelet A, Guillemont J, Bald D, Andries K. 2008. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283:25273-25280. http://dx.doi.org/10.1074/jbc.M803899200.
56. Andries K, Verhasselt P, Guillemont J, Göhlmann HWH, Neefs J-M, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/10.1126/science.1106753.
57. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 2012. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380:986-993. http://dx.doi.org/10.1016/S0140-6736(12)61080-0.
58. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, Krab K, Vergauwen K, Guillemont J, Andries K, Lill H, Koul A, Bald D. 2009. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother. 53: 1290-1292. http://dx.doi.org/10. 1128/AAC.01393-08.
59. Tran SL, Cook GM. 2005. The F1F0-ATP synthase of Mycobacterium smegmatis is essential for growth. J. Bacteriol. 187:5023-5028. http://dx.doi.org/10.1128/ JB.187.14.5023-5028.2005.
60. Khan SR, Singh S, Roy KK, Akhtar MS, Saxena AK, Krishnan MY. 8 November 2012. Biological evaluation of novel substituted chloroquinolines targeting mycobacterial ATP synthase. Int. J. Antimicrob. Agents http://dx.doi.org/10. 1016/j.ijantimicag.2012.09.012.
61. Chung HJ, Montville TJ, Chikindas ML. 2000. Nisin depletes ATP and proton motive force in mycobacteria. Lett. Appl. Microbiol. 31:416-420. http://dx.doi.org/10.1046/j.1472-765x.2000.00840.x.
62. Carroll J, Draper LA, O'Connor PM, Coffey A, Hill C, Ross RP, Cotter PD, O'Mahony J. 2010. Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria. Int. J. Antimicrob. Agents 36:132-136. http://dx.doi.org/10.1016/j.ijantimicag.2010.03.029.
63. Islam MR, Nagao J, Zendo T, Sonomoto K. 2012. Antimicrobial mechanism of lantibiotics. Biochem. Soc. Trans. 40:1528-1533. http://dx.doi.org/10.1042/ BST20120190.
64. Montville TJ, Chung HJ, Chikindas ML, Chen Y. 1999. Nisin A depletes intracellular ATP and acts in bactericidal manner against Mycobacterium smegmatis. Lett. Appl. Microbiol. 28:189-193. http://dx.doi.org/10.1046/j.1365- 2672.1999.00511.x.
65. Ruhr E, Sahl HG. 1985. Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles. Antimicrob. Agents Chemother. 27:841-845. http://dx.doi.org/10.1128/AAC.27.5.841.
66. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. 2003. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52:790-795. http://dx.doi.org/10.1093/jac/dkg446.
67. Zhang Y, Permar S, Sun Z. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:42-49.
68. Huang Q, Chen Z-F, Li Y-Y, Zhang Y, Ren Y, Fu Z, Xu S-Q. 2007.Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. Chemotherapy 53:338-343. http://dx.doi.org/10.1159/000107723.
69. Manca C, Koo MS, Peixoto B, Fallows D, Kaplan G, Subbian S. 2013. Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection. PLoS One 8:e74082. http://dx.doi.org/10.1371/journal.pone.0074082.
70. Jones PB, Parrish NM, Houston TA, Stapon A, Bansal NP, Dick JD, Townsend CA. 2000. A new class of antituberculosis agents. J. Med. Chem. 43:3304-3314. http://dx.doi.org/10.1021/jm000149l.
71. Parrish NM, Houston T, Jones PB, Townsend C, Dick JD. 2001. In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis. Antimicrob. Agents Chemother. 45:1143-1150. http://dx.doi.org/10.1128/AAC.45.4.1143-1150.2001.
72. Parrish NM, Ko CG, Dick JD. 2009. Activity of DSA against anaerobically adapted Mycobacterium bovis BCG in vitro. Tuberculosis (Edinb) 89:325-327. http://dx.doi.org/10.1016/j.tube.2009.05.002.
73. Parrish NM, Ko CG, Hughes MA, Townsend CA, Dick JD. 2004. Effect of n-octanesulphonylacetamide (OSA) on ATP and protein expression in Mycobacterium bovis BCG. J. Antimicrob. Chemother. 54:722-729. http://dx.doi.org/10.1093/jac/ dkh408.
74. Barry CE, Boshoff HIM, Dowd CS. 2004. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des. 10:3239-3262. http://dx.doi.org/10.2174/1381612043383214.
75. Manjunatha U, Boshoff HI, Barry CE. 2009. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun. Integr. Biol. 2:215-218. http://dx.doi.org/10.4161/cib.2.3.7926.
76. Singh R, Manjunatha U, Boshoff HIM, Ha YH, Niyomrattanakit P, Ledwidge R, Dowd CS, Lee IY, Kim P, Zhang L, Kang S, Keller TH, Jiricek J, Barry CE. 2008. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322:1392-1395. http://dx.doi.org/10.1126/science.1164571.
77. Abrahams KA, Cox JA, Spivey VL, Loman NJ, Pallen MJ, Constantinidou C, Fernandez R, Alemparte C, Remuinan MJ, Barros D, Ballell L, Besra GS. 2012. Identification of novel imidazo[1,2-A]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS One 7:e52951. http://dx.doi.org/10.1371/journal.pone. 0052951.
78. Moraski GC, Markley LD, Cramer J, Hipskind PA, Boshoff H, Bailey M, Alling T, Ollinger J, Parish T, Miller MJ. 2013. Advancement of imidazo[1,2-A]pyridines with improved pharmacokinetics and nanomolar activity against Mycobacterium tuberculosis. ACS Med. Chem. Lett. 4:675-679. http://dx.doi.org/10.1021/ml400088y.
79. Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, Christophe T, Lee H, Kempf M, Jackson M, Lenaerts AJ, Pham H, Jones V, Seo MJ, Kim YM, Seo M, Seo JJ, Park D, Ko Y, Choi I, Kim R, Kim SY, Lim S, Yim SA, Nam J, Kang H, Kwon H, Oh CT, Cho Y, Jang Y, Kim J, Chua A, Tan BH, Nanjundappa MB, Rao SP, Barnes WS, Wintjens R, Walker JR, Alonso S, Lee S, Oh S, Oh T, Nehrbass U, Han SJ, No Z, Lee J, Brodin P, Cho SN, Nam K. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med. 19: 1157-1160. http://dx.doi.org/10.1038/nm.3262.
80. Amaral L, Kristiansen JE, Viveiros M, Atouguia J. 2001. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J. Antimicrob. Chemother. 47: 505-511. http://dx.doi.org/10.1093/jac/47.5.505.
81. Martins M, Schelz Z, Martins A, Molnar J, Hajos G, Riedl Z, Viveiros M, Yalcin I, Aki-Sener E, Amaral L. 2007. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 29:338-340. http://dx.doi.org/10.1016/j.ijantimicag.2006.10.013.
82. Martins M, Viveiros M, Kristiansen JE, Molnar J, Amaral L. 2007. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 21:771-775.
83. Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, Martins M, Kristiansen JE, Molnar J, Amaral L. 2003. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:917-922. http://dx.doi.org/10.1128/AAC.47.3. 917-922.2003.
84. van Ingen J, van der Laan T, Amaral L, Dekhuijzen R, Boeree MJ, van Soolingen D. 2009. In vitro activity of thioridazine against mycobacteria. Int. J. Antimicrob. Agents 34:190-191. http://dx.doi.org/10.1016/j.ijantimicag.2009. 02.015.
85. Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D. 2010. Thioridazine cures extensively drug-resistant tuberculosis (XDRTB) and the need for global trials is now! Int. J. Antimicrob. Agents 35:524-526. http://dx.doi.org/10.1016/j.ijantimicag.2009.12.019.
86. Musuka S, Srivastava S, Dona CWS, Meek C, Leff R, Pasipanodya J, Gumbo T. 16 September 2013. Thioridazine pharmacokineticpharmacodynamic parameters "wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. Antimicrob. Agents Chemother. http://dx.doi.org/10.1128/AAC.00829-13.
87. Rodrigues L, Wagner D, Viveiros M, Sampaio D, Couto I, Vavra M, Kern WV, Amaral L. 2008. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. J. Antimicrob. Chemother. 61:1076-1082. http://dx.doi.org/10.1093/jac/dkn070.
88. Yano T, Li L-S, Weinstein E, Teh J-S, Rubin H. 2006. Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). J. Biol. Chem. 281:11456-11463. http://dx.doi.org/10.1074/jbc.M508844200.
89. Tasneen R, Li S-Y, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. 2011. Sterilizing activity of novel TMC207-And PA-824-containing regimens in a murine model of tuberculosis. Antimicrob. Agents Chemother. 55:5485-5492. http://dx.doi.org/10.1128/AAC.05293-11.
90. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL. 2012. Sterilizing activities of novel combinations lacking first-And second-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 56: 3114-3120. http://dx.doi.org/10. 1128/AAC.00384-12.
91. Paulsen IT, Brown MH, Skurray RA. 1996. Proton-dependent multidrug efflux systems. Microbiol. Rev. 60:575-608.
92. Chang G. 2003. Multidrug resistance ABC transporters. FEBS Lett. 555: 102-105. http://dx.doi.org/10.1016/S0014-5793(03)01085-8.
93. Kuroda T, Tsuchiya T. 2009. Multidrug efflux transporters in the MATE family. Biochim. Biophys. Acta 1794:763-768. http://dx.doi.org/10.1016/j.bbapap. 2008.11.012.
94. Hrycyna CA, Gottesman MM. 1998. Multidrug ABC transporters from bacteria to man: an emerging hypothesis for the universality of molecular mechanism and function. Drug Resist. Updat. 1:81-83. http://dx.doi.org/10.1016/S1368-7646(98) 80019-8.
95. van Veen HW, Konings WN. 1997. Multidrug transporters from bacteria to man: similarities in structure and function. Semin. Cancer Biol. 8:183-191. http://dx.doi.org/10.1006/scbi.1997.0064.
96. Yan N. 2013. Structural advances for the major facilitator superfamily (MFS) transporters. Trends Biochem. Sci. 38:151-159. http://dx.doi.org/10.1016/ j.tibs.2013.01.003.
97. Fluman N, Bibi E. 2009. Bacterial multidrug transport through the lens of the major facilitator superfamily. Biochim. Biophys. Acta 1794:738-747. http://dx.doi.org/10.1016/j.bbapap.2008.11.020.
98. Lewinson O, Adler J, Sigal N, Bibi E. 2006. Promiscuity in multidrug recognition and transport: the bacterial MFS Mdr transporters. Mol. Microbiol. 61:277-284. http://dx.doi.org/10.1111/j.1365-2958.2006.05254.x.
99. Law CJ, Maloney PC, Wang DN. 2008. Ins and outs of major facilitator superfamily antiporters. Annu. Rev. Microbiol. 62:289-305. http://dx.doi.org/10. 1146/annurev.micro.61.080706.093329.
100. Paulsen IT, Brown MH, Dunstan SJ, Skurray RA. 1995. Molecular characterization of the staphylococcal multidrug resistance export protein QacC. J. Bacteriol. 177:2827-2833.
101. Grinius L, Dreguniene G, Goldberg EB, Liao CH, Projan SJ. 1992. A staphylococcal multidrug resistance gene product is a member of a new protein family. Plasmid 27:119-129. http://dx.doi.org/10.1016/0147-619X(92)90012-Y.
102. Grinius LL, Goldberg EB. 1994. Bacterial multidrug resistance is due to a single membrane protein which functions as a drug pump. J. Biol. Chem. 269:29998-30004.
103. Alvarez-Ortega C, Olivares J, Martinez JL. 2013. RND multidrug efflux pumps: what are they good for? Front. Microbiol. 4:7. http://dx.doi.org/10.3389/ fmicb.2013.00007.
104. Nikaido H. 2011. Structure and mechanism of RND-type multidrug efflux pumps. Adv. Enzymol. Relat. Areas Mol. Biol. 77:1-60.
105. Nikaido H, Takatsuka Y. 2009. Mechanisms of RND multidrug efflux pumps. Biochim. Biophys. Acta 1794:769-781. http://dx.doi.org/10.1016/j.bbapap.2008.10. 004.
106. Mima T, Sekiya H, Mizushima T, Kuroda T, Tsuchiya T. 2005. Gene cloning and properties of the RND-type multidrug efflux pumps MexPQ-OpmE and MexMN-OprM from Pseudomonas aeruginosa. Microbiol. Immunol. 49:999-1002. http://dx.doi.org/10.1111/j.1348-0421.2005.tb03696.x.
107. Amaral L, Martins M, Viveiros M. 2007. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother. 59:1237-1246. http://dx.doi.org/10.1093/jac/dkl500.
108. De Rossi E, Ainsa JA, Riccardi G. 2006. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol. Rev. 30:36-52. http://dx.doi.org/10.1111/j.1574-6976.2005.00002.x.
109. Calgin MK, Sahin F, Turegun B, Gerceker D, Atasever M, Koksal D, Karasartova D, Kiyan M. 2013. Expression analysis of efflux pump genes among drug-susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates and reference strains. Diagn. Microbiol. Infect. Dis. 76:291-297. http://dx.doi.org/10.1016/j.diagmicrobio.2013.02.033.
110. Danilchanka O, Mailaender C, Niederweis M. 2008. Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52:2503-2511. http://dx.doi.org/10.1128/AAC.00298-08.
111. Milano A, Pasca MR, Provvedi R, Lucarelli AP, Manina G, Ribeiro AL, Manganelli R, Riccardi G. 2009. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis (Edinb) 89:84-90. http://dx.doi.org/10.1016/j.tube.2008.08.003.
112. Dinesh N, Sharma S, Balganesh M. 2013. Involvement of efflux pumps in the resistance to peptidoglycan synthesis inhibitors in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57:1941-1943. http://dx.doi.org/10.1128/AAC. 01957-12.
113. Sharma S, Kumar M, Nargotra A, Koul S, Khan IA. 2010. Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobac-terium tuberculosis. J. Antimicrob. Chemother. 65:1694-1701. http://dx.doi.org/10.1093/ jac/dkq186.
114. Jiang X, Zhang W, Zhang Y, Gao F, Lu C, Zhang X, Wang H. 2008. Assessment of efflux pump gene expression in a clinical isolate Mycobacterium tuberculosis by real-time reverse transcription PCR. Microb. Drug Resist. 14:7-11. http://dx.doi.org/10.1089/mdr.2008.0772.
115. Siddiqi N, Das R, Pathak N, Banerjee S, Ahmed N, Katoch VM, Hasnain SE. 2004. Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection 32:109-111. http://dx.doi.org/ 10.1007/s15010-004-3097-x.
116. Gupta AK, Chauhan DS, Srivastava K, Das R, Batra S, Mittal M, Goswami P, Singhal N, Sharma VD, Venkatesan K, Hasnain SE, Katoch VM. 2006. Estimation of efflux mediated multi-drug resistance and its correlation with expression levels of two major efflux pumps in mycobacteria. J. Commun. Dis. 38:246-254.
117. Braibant M, Gilot P, Content J. 2000. The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. FEMS Microbiol. Rev. 24:449-467. http://dx.doi.org/10.1111/j.1574-6976.2000.tb00550.x.
118. Hao P, Shi-Liang Z, Ju L, Ya-Xin D, Biao H, Xu W, Min-Tao H, Shou-Gang K, Ke W. 2011. The role of ABC efflux pump, Rv1456c-Rv1457c-Rv1458c, from Mycobacterium tuberculosis clinical isolates in China. Folia Microbiol. (Praha) 56:549-553. http://dx.doi.org/10.1007/s12223-011-0080-7.
119. De Rossi E, Arrigo P, Bellinzoni M, Silva PA, Martin C, Ainsa JA, Guglierame P, Riccardi G. 2002. The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Mol. Med. 8:714-724.
120. Li XZ, Zhang L, Nikaido H. 2004. Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob. Agents Chemother. 48:2415-2423. http://dx.doi.org/10.1128/AAC.48.7.2415-2423.2004.
121. Chatterjee A, Saranath D, Bhatter P, Mistry N. 2013. Global transcriptional profiling of longitudinal clinical isolates of Mycobacterium tuberculosis exhibiting rapid accumulation of drug resistance. PLoS One 8:e54717. http://dx.doi.org/10.1371/journal.pone.0054717.
122. Gopinath K, Venclovas C, Ioerger TR, Sacchettini JC, McKinney JD, Mizrahi V, Warner DF. 2013. A vitamin B12 transporter in Mycobacterium tuberculosis. Open Biol. 3:120175. http://dx.doi.org/10.1098/rsob.120175.
123. Gupta AK, Katoch VM, Chauhan DS, Sharma R, Singh M, Venkatesan K, Sharma VD. 2010. Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs. Microb. Drug Resist. 16:21-28. http://dx.doi.org/10.1089/mdr.2009.0054.
124. Ramón-García S, Martin C, De Rossi E, Ainsa JA. 2007. Contribution of the Rv2333c efflux pump (the Stp protein) from Mycobacterium tuberculosis to intrinsic antibiotic resistance in Mycobacterium bovis BCG. J. Antimicrob. Chemother. 59:544-547. http://dx.doi.org/10.1093/jac/dkl510.
125. Machado D, Couto I, Perdigao J, Rodrigues L, Portugal I, Baptista P, Veigas B, Amaral L, Viveiros M. 2012. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One 7:e34538. http://dx.doi.org/10.1371/journal.pone.0034538.
126. Gupta AK, Reddy VP, Lavania M, Chauhan DS, Venkatesan K, Sharma VD, Tyagi AK, Katoch VM. 2010. jefA (Rv2459), a drug efflux gene in Mycobacterium tuberculosis confers resistance to isoniazid & ethambutol. Indian J. Med. Res. 132:176-188.
127. Pasca MR, Guglierame P, Arcesi F, Bellinzoni M, De Rossi E, Riccardi G. 2004. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48:3175-3178. http://dx.doi.org/10.1128/AAC.48.8.3175-3178.2004.
128. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Hernandez-Pando R, McEvoy CRE, Grobbelaar M, Murray M, van Helden PD, Victor TC. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184:269-276. http://dx.doi.org/10.1164/rccm.201011-1924OC.
129. Pang Y, Lu J, Wang Y, Song Y, Wang S, Zhao Y. 2013. Study of rifampicin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57:893-900. http://dx.doi.org/10.1128/AAC.01024-12.
130. Choudhuri BS, Bhakta S, Barik R, Basu J, Kundu M, Chakrabarti P. 2002. Overexpression and functional characterization of an ABC (ATPbinding cassette) transporter encoded by the genes drrA and drrB of Mycobacterium tuberculosis. Biochem. J. 367:279-285. http://dx.doi.org/10.1042/BJ20020615.
131. Doran JL, Pang Y, Mdluli KE, Moran AJ, Victor TC, Stokes RW, Mahenthiralingam E, Kreiswirth BN, Butt JL, Baron GS, Treit JD, Kerr VJ, Van Helden PD, Roberts MC, Nano FE. 1997. Mycobacterium tuberculosis efpA encodes an efflux protein of the QacA transporter family. Clin. Diagn. Lab. Immunol. 4:23-32.
132. Wilson M, DeRisi J, Kristensen HH, Imboden P, Rane S, Brown PO, Schoolnik GK. 1999. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc. Natl. Acad. Sci. U. S. A. 96:12833-12838. http://dx.doi.org/10.1073/pnas.96.22.12833.
133. De Rossi E, Branzoni M, Cantoni R, Milano A, Riccardi G, Ciferri O. 1998. mmr, a Mycobacterium tuberculosis gene conferring resistance to small cationic dyes and inhibitors. J. Bacteriol. 180:6068-6071.
134. Choudhuri BS, Sen S, Chakrabarti P. 1999. Isoniazid accumulation in Mycobacterium smegmatis is modulated by proton motive force-driven and ATP-dependent extrusion systems. Biochem. Biophys. Res. Commun. 256:682-684. http://dx.doi.org/10.1006/bbrc.1999.0357.
135. Colangeli R, Helb D, Sridharan S, Sun J, Varma-Basil M, Hazbon MH, Harbacheuski R, Megjugorac NJ, Jacobs WR, Jr, Holzenburg A, Sacchettini JC, Alland D. 2005. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol. Microbiol. 55:1829-1840. http://dx.doi.org/10.1111/j.1365-2958. 2005.04510.x.
136. Domenech P, Reed MB, Barry CE. 2005. Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect. Immun. 73:3492-3501. http://dx.doi.org/10.1128/IAI.73.6.3492-3501.2005.
137. Banerjee SK, Bhatt K, Rana S, Misra P, Chakraborti PK. 1996. Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis. Biochem. Biophys. Res. Commun. 226:362-368. http://dx.doi.org/10.1006/bbrc.1996.1362.
138. Sarin J, Aggarwal S, Chaba R, Varshney GC, Chakraborti PK. 2001. B-subunit of phosphate-specific transporter from Mycobacterium tuberculosis is a thermostable ATPase. J. Biol. Chem. 276:44590-44597. http://dx.doi.org/10.1074/ jbc.M105401200.
139. Schmalstieg AM, Srivastava S, Belkaya S, Deshpande D, Meek C, Leff R, van Oers NSC, Gumbo T. 2012. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob. Agents Chemother. 56: 4806-4815. http://dx.doi.org/10. 1128/AAC.05546-11.
140. Piddock LJ, Williams KJ, Ricci V. 2000. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. J. Antimicrob. Chemother. 45:159-165. http://dx.doi.org/10.1093/jac/45.2.159.
141. Louw GE, Warren RM, Gey van Pittius NC, McEvoy CRE, Van Helden PD, Victor TC. 2009. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob. Agents Chemother. 53:3181-3189. http://dx.doi.org/10.1128/AAC.01577- 08.
142. Singh M, Jadaun GPS, Ramdas Srivastava K, Chauhan V, Mishra R, Gupta K, Nair S, Chauhan DS, Sharma VD, Venkatesan K, Katoch VM. 2011. Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J. Med. Res. 133:535-540.
143. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR. 2014. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58:574-576. http://dx.doi.org/10.1128/AAC.01462- 13.
144. Balganesh M, Dinesh N, Sharma S, Kuruppath S, Nair AV, Sharma U. 6 February 2012. Efflux pumps of Mycobacterium tuberculosis play a significant role in anti-tuberculosis activity of potential drug candidates. Antimicrob. Agents Chemother. http://dx.doi.org/10.1128/AAC.06003-11.
145. Balganesh M, Kuruppath S, Marcel N, Sharma S, Nair A, Sharma U. 2010. Rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery. Antimicrob. Agents Chemother. 54: 5167-5172. http://dx.doi.org/10.1128/AAC.00610-10.
146. Burian J, Ramon-Garcia S, Howes CG, Thompson CJ. 2012. WhiB7, a transcriptional activator that coordinates physiology with intrinsic drug resistance in Mycobacterium tuberculosis. Expert Rev. Anti Infect. Ther. 10:1037-1047. http://dx.doi.org/10.1586/eri.12.90.
147. Burian J, Ramón-García S, Sweet G, Gómez-Velasco A, Av-Gay Y, Thompson CJ. 2012. The mycobacterial transcriptional regulator whiB7 gene links redox homeostasis and intrinsic antibiotic resistance. J. Biol. Chem. 287:299-310. http://dx.doi.org/10.1074/jbc.M111.302588.
148. Morris RP, Nguyen L, Gatfield J, Visconti K, Nguyen K, Schnappinger D, Ehrt S, Liu Y, Heifets L, Pieters J, Schoolnik G, Thompson CJ. 2005. Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 102:12200-12205. http://dx.doi.org/10.1073/pnas.0505446102.
149. Li Y, Zeng J, Zhang H, He ZG. 2010. The characterization of conserved binding motifs and potential target genes for M. tuberculosis MtrAB reveals a link between the two-component system and the drug resistance of M. smegmatis. BMC Microbiol. 10:242. http://dx.doi.org/10.1186/1471-2180-10-242.
150. Bolla JR, Do SV, Long F, Dai L, Su CC, Lei HT, Chen X, Gerkey JE, Murphy DC, Rajashankar KR, Zhang Q, Yu EW. 2012. Structural and functional analysis of the transcriptional regulator Rv3066 of Mycobacterium tuberculosis. Nucleic Acids Res. 40:9340-9355. http://dx.doi.org/10.1093/nar/gks677.
151. de Knegt GJ, Bruning O, ten Kate MT, de Jong M, van Belkum A, Endtz HP, Breit TM, Bakker-Woudenberg IAJM, de Steenwinkel JEM. 2013. Rifampicin-induced transcriptome response in rifampicinresistant Mycobacterium tuberculosis. Tuberculosis (Edinb) 93:96-101. http://dx.doi.org/10.1016/j.tube.2012.10.013.
152. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, Edelstein PH, Cosma CL, Ramakrishnan L. 2011. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145:39-53. http://dx.doi.org/10.1016/j.cell.2011.02.022.
153. van Veen HW, Venema K, Bolhuis H, Oussenko I, Kok J, Poolman B, Driessen AJ, Konings WN. 1996. Multidrug resistance mediated by a bacterial homolog of the human multidrug transporter MDR1. Proc. Natl. Acad. Sci. U. S. A. 93:10668-10672. http://dx.doi.org/10.1073/pnas.93.20.10668.
154. Tanaka Y, Hipolito CJ, Maturana AD, Ito K, Kuroda T, Higuchi T, Katoh T, Kato HE, Hattori M, Kumazaki K, Tsukazaki T, Ishitani R, Suga H, Nureki O. 2013. Structural basis for the drug extrusion mechanism by a MATE multidrug transporter. Nature 496:247-251. http://dx.doi.org/10.1038/nature12014.
155. Bolhuis H, Molenaar D, Poelarends G, van Veen HW, Poolman B, Driessen AJ, Konings WN. 1994. Proton motive force-driven and ATPdependent drug extrusion systems in multidrug-resistant Lactococcus lactis. J. Bacteriol. 176:6957-6964.
156. Bolhuis H, van Veen HW, Brands JR, Putman M, Poolman B, Driessen AJ, Konings WN. 1996. Energetics and mechanism of drug transport mediated by the lactococcal multidrug transporter LmrP. J. Biol. Chem. 271:24123-24128. http://dx.doi.org/10.1074/jbc.271.39.24123.
157. Zeller V, Janoir C, Kitzis MD, Gutmann L, Moreau NJ. 1997. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1973-1978.
158. Ezraty B, Vergnes A, Banzhaf M, Duverger Y, Huguenot A, Brochado AR, Su SY, Espinosa L, Loiseau L, Py B, Typas A, Barras F. 2013. Fe-S cluster biosynthesis controls uptake of aminoglycosides in a ROS-less death pathway. Science 340:1583-1587. http://dx.doi.org/10.1126/science.1238328.
159. Jiang T, Zhan Y, Sun M, Liu S, Zang S, Ma Y, Xin Y. 2011. The novel responses of ethambutol against Mycobacterium smegmatis mc2155 revealed by proteomics analysis. Curr. Microbiol. 62:341-345. http://dx.doi.org/10.1007/ s00284-010-9711-5.
160. Fu LM, Shinnick TM. 2007. Genome-wide exploration of the drug action of capreomycin on Mycobacterium tuberculosis using Affymetrix oligonucleotide GeneChips. J. Infect. 54:277-284. http://dx.doi.org/10.1016/j.jinf.2006.05.012.
161. Allen HK, Donato J, Wang HH, Cloud-Hansen KA, Davies J, Handelsman J. 2010. Call of the wild: antibiotic resistance genes in natural environments. Nat. Rev. Microbiol. 8:251-259. http://dx.doi.org/10.1038/nrmicro2312.